Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Pharma
Akeso CEO tries to reset expectations of bispecific's OS readout
The interpretation of ivonescimab’s overall survival data from the HARMONi-2 trial has “deviated from the core of the issue,” Akeso's CEO said.
Angus Liu
Apr 28, 2025 6:50am
Summit stock falls as Akeso shares bispecific OS data vs. Keytruda
Apr 25, 2025 4:02pm
Akeso's fast-rising ivonescimab scores 3rd lung cancer trial win
Apr 23, 2025 11:30am
Merck lays out subcutaneous Keytruda data amid patent brawl
Mar 27, 2025 11:00am
J&J combo survival win signals new era in EGFR lung cancer
Mar 26, 2025 11:45am
AZ offers early look at Datroway-Tagrisso combo in lung cancer
Mar 19, 2025 7:05pm
.jpg?VersionId=5HoajupHCiKKFzt_zOi.f2WkioAd04QW)
